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Abstract
Background: Sepsis is associated with coagulation abnormalities, and a high content of intravascular tissue factor
(TF) may contribute to the development of multisystem organ failure. Circulating microvesicles (MVs) are increased
during sepsis and characterized by their phosphatidylserine content. It is unclear whether MVs—as a part of the
host response to the infection—are beneficial or rather contribute to systemic complications in sepsis. In the
present prospective clinical pilot study, we investigated whether plasma TF and MVs are associated with the risk of
multiple organ failure and mortality.
Methods: Thirty patients diagnosed with sepsis, severe sepsis, or septic shock were enrolled and classified as 19
survivors and 11 non-survivors. Blood samples were collected on the day of admission and then daily for up to
2 weeks. MVs and TF were quantified in plasma by ELISA.
Results: Non-survivors had significantly higher TF concentrations on day 3 compared to survivors. Logistic
regression analysis revealed that patients with high amounts of TF had significantly increased risk for severity of
disease, according to high Simplified Acute Physiology Score II (SAPS II) scores (odds ratio 18.7). In contrast, a higher
content of phosphatidylserine-rich MVs were apparently associated with a lower risk for mortality and multiple
organ failure, although this was only a trend and the odds ratios were not significant.
Conclusions: This study showed that a high amount of TF in septic patients is significantly associated with
increased risk for disease severity, according to a high SAPS II score. Quantification of total MVs in plasma,
independent from their cell origin, might be indicative for the outcome of patients in sepsis.
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Background
Sepsis is a serious medical condition caused by an over-
whelming immune response to an infection. It is often as-
sociated with bacteremia and characterized by systemic
signs and symptoms of inflammation [1].
Fifty to 70 % of patients with sepsis develop coagulation
abnormalities that range from minor to hyper activation
of coagulation. Hyper activation of coagulation frequently
causes excess fibrin deposition characterized by simultan-
eous widespread microvascular thrombosis and profuse
bleeding from various sites [2].
The principal initiator of coagulation is tissue factor.
Tissue factor (TF) is a transmembrane glycoprotein that
triggers blood coagulation via binding factor (F) VIIa and
FX with subsequent thrombin generation and fibrin clot
propagation. Following vessel injury, TF is exposed to
blood and activates the clotting system, which prevents
excess blood loss and seals the wound. Under normal con-
ditions, TF is exclusively expressed in vascular and tissue
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cells that have no direct contact with blood. However, this
concept is outdated as evidence supports the presence of
intravascular TF, also described as “circulating” or “blood-
borne” TF [3]. The cellular source of TF in blood is still a
matter of discussion, but it has been concluded that
monocytes are the only blood cells that synthesize and
express TF [4]. Several groups demonstrated higher levels
of intravascular TF in septic patients [5–8].
It is unclear how TF circulates, although it has been
described that TF is transported on membrane vesicles.
Membrane vesicles are sphere-shaped structures, less than
1 μm of diameter and limited by a lipid bilayer. They can
be secreted from all human blood-born cells and are com-
monly classified according to their formation mechanism
and their size. Membrane vesicles with a size between 100
and 1000 nm are called microparticles or microvesicles
and shed from the cell plasma membrane, while exosomes
are 50–100-nm vesicles that are secreted by cells via exo-
cytosis [9]. The outer surface of membrane vesicles and
exosomes is enriched in negatively charged phosphatidyl-
serine (PS), which provides a catalytic surface for many
plasma proteins including contact and coagulation factors
[10]. Beyond its function in coagulation, PS is also in-
volved in clearance of apoptotic cells and modulation of
the immune system [11]. In this paper, the term MVs will
be used to designate all types of cell-derived microvesicles
that are PS-rich and found in plasma, independent of their
size. Depending on cell activation, MVs differ in their
composition and function. Elevated levels of MVs have
been related to pathological conditions such as bleeding
and thrombotic disorders, cardiovascular diseases, cancer,
and sepsis [12, 13].
Due to their small size, PS-rich MVs offer an add-
itional phospholipid platform that has approximately 50-
to 100-fold more pro-coagulant activity than activated
platelets [14]. We recently reported that the number of
total PS-rich MVs in plasma was significantly increased in
patients suffering from sepsis [15]. Moreover, in another
study, we found a significant increase of total MVs in a
mouse streptococcal sepsis model, suggesting that their
release is an immune response to the infection [16]. As
described above, MVs are supposed to be the most
important reservoir for intravascular TF; they may transfer
and deliver TF to target cells, such as platelets and neutro-
phils, thereby amplifying and disseminating the pro-
coagulant response [10].
These findings raised the question whether MVs—as a
part of the host response to the infection—are beneficial
or rather contribute to systemic complications in sepsis.
In the present prospective clinical pilot study, we investi-
gated the concentration of plasma TF and total MVs in
30 septic patients and evaluated whether both parame-




Thirty patients with sepsis (n = 6), severe sepsis (n = 4), or
septic shock (n = 20) were included in this pilot study.
Patients were enrolled from the Intensive Care Medicine
Unit at University Medical Center of Rostock. The proto-
col had been approved by our Institutional Ethics commit-
tee (A 201151), and informed consent was obtained from
the patients or their caring relatives.
All patients were diagnosed according to the guide-
lines of ACCP/SCCM-Consensus Conference (American
College of Chest Physicians/Society of Critical Care
Medicine), defined as those patients meeting two of the
four systemic inflammatory response syndrome criteria
together with an infectious process [17].
The following demographic data were collected at
admission in the ICU: age, gender, Simplified Acute
Physiology Score II (SAPS II) [10], and Sequential Organ
Failure Assessment (SOFA) [12].
Sampling and methods
Blood samples were collected as patients were diagnosed
with sepsis and then daily for up to 7 days, depending on
the patient. After 1 week, sampling occurred every second
day until day 13. A minimum of two samples and a max-
imum of 10 samples were derived from a patient. The
average study period was 8.6 days. Immediately after blood
samples were taken, the blood was centrifuged at 1500×g,
for 20 min at 21 °C. The resulting platelet-poor plasma
obtained was centrifuged again, at 10,000×g, for 5 min
and 21 °C. The platelet-free plasma obtained after the
second centrifugation was stored at −80 °C until analysis.
Total MVs were quantified by a prothrombinase assay
that detect PS exposed at the MV surface (ACTICHROME
®MP- Activity ELISA kit, American Diagnostica, USA),
according to the instruction of the manufacturer. In this
assay, PS-positive MVs bind to Annexin V and expose their
PS-rich surface, allowing Factor Xa-Va in the presence of
calcium to activate prothrombin into thrombin. The PS
concentration is the limiting factor. There is a direct rela-
tionship between the PS present on the MVs and the
amount of thrombin generation, which is measured via its
specific activity on the thrombin substrate. Results were
expressed as nanomolar PS by reference to a standard
curve established with liposomes of known concentration.
Quantitative tissue factor antigen concentrations in
plasma were determined by an enzyme-linked immuno-
assay (IMUBIND Tissue Factor ELISA kit, American
Diagnostica, USA), according to the instruction of the
manufacturer. This assay recognizes TF-apo, TF, and
TF-VII complexes and is designed such that there is no
interference from other coagulation factors or inhibitors
of pro-coagulant activity.
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Western blot analyses were performed with sheep anti-
bodies against human high molecular kininogen (Affinity
Biologicals) and its degradation products as described pre-
viously [18].
Statistics
All data were stored and analyzed using the SPSS statistical
package 20.0 (SPSS Inc. Chicago, Illinois, USA). Descriptive
statistics were computed for continuous and categorical
variables. The computed statistics included mean and
standard deviations or median and interquartile range of
continuous variables, frequencies, and relative frequencies
of categorical factors. Testing for the differences of continu-
ous variables between the study groups was accomplished
by the two-sample t test for independent samples or the
Mann-Whitney U test, as appropriate. Test selection was
based on evaluating the variables for normal distribution
employing the Kolmogorov-Smirnov test.
The logistic regression model was used to assess
whether TF or MVs can predict risk of mortality, high
SAPS II, and SOFA score. According to their average con-
tent of PS and TF, patients were divided into three groups
and odds ratios as well as 95 % confidence intervals (95 %
CI) were calculated for the outcome of survival, high
SAPS II, and SOFA score while one of the groups was
used as a reference group. All values resulted from two-
sided statistical tests, and p ≤ 0.05 was considered to be
significant.
Availability of data and materials
The dataset supporting the conclusions of this article is




The clinical and laboratory data of our patient population
are summarized in Table 1. Thirty patients were investi-
gated, 13 (43.3 %) were female and 17 (56.7 %) male. The
age ranged between 21 and 84 years; the mean age was
61.03 years. Survivors were younger than non-survivors but
not significantly (Table 1). From 30 patients, 19 (63.3 %)
survived, whereas 11 (36.7 %) died on ICU. The SAPS II
and SOFA scores of non-survivors were significantly higher
compared to those of survivors (Table 1). Further on, the
activated partial thromboplastin time (aPTT) as a single
parameter was significantly prolonged in non-survivors.
The aPTT is a marker for the intrinsic coagulation path-
way, and the data suggest a consumption of contact factors
in non-survivors. However, the prolonged aPTT was not
associated with degradation of high molecular weight kinin-
ogen in these patients (data not shown).
Other parameters such as platelet count, white blood
cell count, and procalcitonin were not significantly differ-
ent between the two groups (Table 1).
In most of the patients, multiple infectious sources
and bacterial isolates were identified (Table 2).
Tissue factor
In septic patients, a systemic activation of the extrinsic
coagulation pathway by TF may contribute to the devel-
opment of multisystem organ failure and subsequent
mortality [19]. TF circulates in the blood in two different
forms: (i) associated with the cellular membrane of white
blood cells, platelets, and cell-derived microvesicles and
(ii) as a soluble protein lacking the transmembrane
domain generated by an alternatively spliced messenger
RNA (mRNA) [20]. The ELISA used in the present study
detects both forms of TF in plasma [21].
Figure 1a depicts the TF concentrations of survivors
and non-survivors on several days. Hereby, a significant
difference between survivors and non-survivors was de-
tected on day 3 (p = 0.031), whereby non-survivors had
higher concentrations (Fig. 1a). The baseline calculation
showed no significant differences (Fig. 1b).
A logistic regression analysis was done. First, the risk
of mortality based on TF quantity was calculated, and
patients were divided into three groups, (i) patients with
high TF concentrations (>300 pg/ml), (ii) patients with
middle TF concentrations (220–300 pg/ml), and (iii)






Age (years, mean ± SD) 58.1 ± 16.9 66.1 ± 16.2 0.215
Gender (% of male) 57.9 54.5 –
SAPS II (mean ± SD) 51.65 ± 19.23 73.69 ± 13.85 0.002*
SOFA (mean ± SD) 8.18 ± 3.52 12.29 ± 1.43 <0.001**





aPTT (s) (mean ± SD) 55.18 ± 10.32 70.46 ± 22.92 0.020*
Platelet count (×10)
(mean ± SD)
209.3 ± 83.1 148.9 ± 72.9 0.055
White blood cell count
(mean ± SD)
14.08 ± 8.61 17.63 ± 9.04 0.293
CRP (mean ± SD) 231.35 ± 99.73 226.79 ± 106.89 0.928
HK (mean ± SD) 0.284 ± 0.032 0.282 ± .021 0.832
Hb (mean ± SD) 5.75 ± 0.65 5.74 ± 0.48 0.952






(nM) (mean ± SD)
18.69 ± 6.13 16.63 ± 6.33 0.388
TF (pg/ml) (mean ± SD) 269.75 ± 171.47 325.22 ± 169.82 0.399
Data are expressed as mean ± SD or median and 25 to 75 % interquartile
range (IQR) *p < 0.05, **p < 0.001
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patients with low TF concentrations (110–220 pg/ml),
who served as the reference group. Patients with middle
and high TF concentrations had a 1.5-fold or 2.6-fold
higher risk to die, compared to patients with a low TF
content (Table 3). Both odds ratios were not significant,
but there is a trend towards increased mortality in pa-
tients with high TF concentrations.
The patients were divided by their SAPS II score,
whereby high SAPS II scores (>60) are accompanied
with a higher risk of mortality. The logistic regression
analysis was done, and patients with low TF quantity
(110–220 pg/ml) were conduced as reference group.
Patients with middle TF quantities (220–300 pg/ml) had
a 3.2-fold higher risk for a high SAPS II score (Table 3),
compared to patients with low TF (110–220 pg/ml).
Patients with high amounts of TF (>300 pg/ml) had a
statistically significant 18.7-fold increased risk for a
SAPS II score above 60 (Table 3), compared to patients
with low TF (110–220 pg/ml).
Analogous to the SAPS II score, the patients were
divided by their SOFA scores and a value between 11
and 20 was the negative event. The logistic regression
analysis showed a 1.46-fold higher risk for patients with
middle TF quantity (220–300 pg/ml) for a high SOFA
score (Table 3). In patients with high TF (>300 pg/ml),
the risk for a SOFA score above 10 (Table 4) was 5.25-
fold higher, compared to the reference group (patients
with low TF 110–220 pg/ml). Although these odds ratios
are not significant, the trend supports the following
hypothesis that a high content of intravascular TF seems
to be associated with a high risk for mortality.
Table 2 Sources and microorganism isolates of patients
Survivors Non-survivors
Respiratory tract Candida albicans 5 Candida albicans 2
Candida galbrata 2
Candida tropicalis 1 Candida tropicalis 1
Aspergillus fumagatus 2 Strepotoccus anginosus 1















Candida albicans 3 Candida albicans 3
Candida krusei Candida galbrata 1
Candida tripolis 1 Candida tropicalis 1










Enterococcus faecalis 4 Enterococcus faecalis 2
Enterococcus faecium 4 Enterococcus faecium 5
Enterobacter cloacae 1







Anaerob mixed flora 2 Anaerob mixed flora 1
Urinary tract Escherichia coli 1 Enterococcus faecium 1
Proteus vulgaris 1

































Main sources and organisms detected in septic patients are represented
MRSA methicillin-resistant Staphylococcus aureus
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Fig. 1 Course of TF antigen in plasma of survivors and non-survivors, depicted as a TF concentration (pg/ml) and b baseline calculation (%).
*p < 0.05 vs. survivors
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PS-positive MVs in plasma
We measured the concentration of PS-positive MVs in
plasma of the septic patients on several days but found
no significant differences in MV concentration between
survivors and non-survivors (Fig. 2a). The baseline
calculation showed no significant differences, although
the mean MV quantity in the non-survivor group was
lower at all days (Fig. 2b).
To calculate the risk of mortality based on MV quantity,
again, a logistic regression analysis was done. Patients
were divided into three groups, (i) patients with high MV
concentrations (>18 nM) as the reference group, (ii)
patients with MV concentrations in the middle range (15–
18 nM), and (iii) patients with MV concentrations in the
low range (0–15 nM, Table 4). Taken all together, odds
ratios implicate that patients with MV concentrations in
the middle and low range had a higher risk for mortality
or a high SAPS II and SOFA score, when compared to the
reference group (Table 4). Although these odds ratios
were not significant; the trend supports the hypothesis
that a higher content of PS-rich MVs could be associated
with a lower risk for mortality.
Discussion
It is now accepted that TF circulates in the blood: (i) as-
sociated with white cells and platelets, (ii) associated
with cell-derived MVs, and (iii) as a soluble protein lack-
ing the transmembrane domain generated by an alterna-
tively spliced mRNA [20]. Only the last two forms are
detectable in plasma. We found significantly elevated TF
concentrations on day 3 in non-survivors of septic pa-
tients in comparison with the survivors. This corre-
sponds to the findings in earlier studies comparing
survivors with non-survivors. Green et al. found a sig-
nificant increased TF concentration even on day 3 in
children with sepsis [6]. Also Gando et al. showed a sig-
nificantly higher TF content on several days in non-
survivors [21]. Assuming that the SAPS II score reflects
severity of sepsis, patients with TF concentrations above
300 pg/ml in our study had a significantly higher risk for
a serious course of sepsis. This was supported by a ten-
dency for higher risk of mortality and SOFA score of
such patients, though these odds ratios were not signifi-
cant. Although several studies reported significant higher
TF concentrations in plasma of septic patients [5–8],
only one study showed a significant correlation between
high TF concentrations and increased mortality [6].
An increase in intravascular TF is an indication of tis-
sue factor production from activated monocytes. MVs
derived from monocytes express and deliver intravascu-
lar TF to sites of pathogen exposure, which initiates
immunothrombosis inside a blood vessel [22]. The re-
lease of MV-associated TF by monocytes may be there-
fore regarded as a physiological element of intravascular
immunity, to detect and protect against pathogens in the
vasculature [23]. However, as we did not found any cor-
relation between TF concentration and total MVs (data
not shown), we assume that only a minor part of the cir-
culating MVs contains TF. Another possible reason may
be that the ELISA used in the present study detects both
MV-associated TF as well as the soluble form of TF.
The pro-coagulant activity of MVs has mainly been
attributed to TF but MVs also elicit phospholipid-
dependent pro-coagulant activity due to the exposure of
PS on their membrane [24]. In an earlier study, we found
increased concentrations of PS-rich MVs in patients
suffering from sepsis compared to healthy persons [15].
As pro-coagulant MVs seem to play a key role in multi-
organ dysfunction and septic shock, it was, therefore,
tempting to speculate that a high amount of total PS-rich
MVs in septic patients is associated with a higher risk for
mortality. Surprisingly, the data of our present study sug-
gest the opposite; a higher content of total MVs was asso-
ciated with a trend to lower risk for mortality in septic
patients, which is in contrast to TF. One could speculate
that the MVs are trapped in the organs; therefore, their
amount in the circulation is lower. But it should be con-
sidered that—behind pathological functions—MVs may be
also beneficial at the early stage of sepsis, as they can com-
pensate for some of the host’s systemic reactions [25]. It
has been reported that elevated levels of platelet, endothe-
lium-, and leukocyte-derived MVs predict a more favor-
able outcome in severe sepsis with regard to mortality and
Table 3 TF antigen concentration and the risk of mortality, high
SAPS II, or SOFA score calculated by logistic regression analysis
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organ dysfunction. The authors support the hypothesis that
an early increased inflammatory response is associated with
improved survival rates [26]. Our recent and actual findings
promote this thesis, showing that formation and release of
PS-rich MVs are a part of the immune response to bacterial
infections [15, 16]. Thus, a high amount of MVs may be a
marker of cell activation and inflammation, reflecting a
potent inflammatory response, necessary to fight against
the infection. A beneficial function for MVs in sepsis was
also supported by a study of Mostefai et al., who showed
that the total number of circulating and platelet MVs in
patients with septic shock was increased. These MVs exert
a protective effect against vascular hyporeactivity by main-
taining a tonic pressure in septic shock [27]. Also, Guervilly
et al. found that high levels of circulating leukocyte MVs
are associated with better outcome in acute respiratory
distress syndrome [28]. Although the mechanism of
protection is not clear, one could hypothesize that the
antibacterial effect of MVs, released from human neutro-
philic granulocytes, restricts bacterial growth and dissem-
ination during sepsis [29]. In a previous study, we have
shown that pro-coagulant MVs can bind to Streptococcus
pyogenes bacteria and promote clotting, entrapment, and
killing of the bacteria in a fibrin network. Thus, an inter-
action of MVs with bacteria may protect the host [16],
which supports the hypothesis above.
A limitation of our pilot study is the relatively small
sample size, which reflects typical cases of a Northeast
German center for intensive care. This means that the
power to detect and label MVs as statistically significant
risk factors for mortality was limited. Thus, our data must
be validated in an independent larger cohorts of sepsis
patients because of the heterogeneity of patients with sepsis
and the fact that disease outcome is related to several
a
b
Fig. 2 Course of MVs in plasma of survivors and non-survivors, depicted as a phosphatidylserine-concentration (nM) and b baseline
calculation (%)
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baseline characteristics [30, 31]. In the future, elucidation of
protective mechanisms of MVs is an emerging challenge to
design new therapeutic strategies.
Conclusions
This study showed that high amounts of intravascular TF
in septic patients significantly increased the risk of disease
severity, according to SAPS II scores above 60. In contrast,
a high amount of PS-rich MVs is not associated with
disease severity or mortality.
Abbreviations
MVs, microvesicles; PS, phosphatidylserine; SAPS II, Simplified Acute Physiology
Score II; SOFA, Sequential Organ Failure Assessment; TF, tissue factor
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